IBDEI1JX ; ; 01-FEB-2022
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 01, 2022
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,25145,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,25145,1,2,0)
 ;;=2^High Intensity Bhv Counsel for STD Prev,30 min
 ;;^UTILITY(U,$J,358.3,25145,1,4,0)
 ;;=4^G0445
 ;;^UTILITY(U,$J,358.3,25146,0)
 ;;=G0459^^88^1130^41^^^^1
 ;;^UTILITY(U,$J,358.3,25146,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,25146,1,2,0)
 ;;=2^Inpt TH Pharm Mgmt
 ;;^UTILITY(U,$J,358.3,25146,1,4,0)
 ;;=4^G0459
 ;;^UTILITY(U,$J,358.3,25147,0)
 ;;=G0446^^88^1130^7^^^^1
 ;;^UTILITY(U,$J,358.3,25147,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,25147,1,2,0)
 ;;=2^Annual Intense Bhv Tx for Cardio Dx,15 min
 ;;^UTILITY(U,$J,358.3,25147,1,4,0)
 ;;=4^G0446
 ;;^UTILITY(U,$J,358.3,25148,0)
 ;;=G0447^^88^1130^13^^^^1
 ;;^UTILITY(U,$J,358.3,25148,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,25148,1,2,0)
 ;;=2^Bhv Counsel for Obesity,15 min
 ;;^UTILITY(U,$J,358.3,25148,1,4,0)
 ;;=4^G0447
 ;;^UTILITY(U,$J,358.3,25149,0)
 ;;=G0506^^88^1130^17^^^^1
 ;;^UTILITY(U,$J,358.3,25149,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,25149,1,2,0)
 ;;=2^Comp Assmt Care Plan CCM Svc
 ;;^UTILITY(U,$J,358.3,25149,1,4,0)
 ;;=4^G0506
 ;;^UTILITY(U,$J,358.3,25150,0)
 ;;=G0513^^88^1130^57^^^^1
 ;;^UTILITY(U,$J,358.3,25150,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,25150,1,2,0)
 ;;=2^Prolong Prev Outpt Svc,1st 30 min
 ;;^UTILITY(U,$J,358.3,25150,1,4,0)
 ;;=4^G0513
 ;;^UTILITY(U,$J,358.3,25151,0)
 ;;=G0514^^88^1130^58^^^^1
 ;;^UTILITY(U,$J,358.3,25151,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,25151,1,2,0)
 ;;=2^Prolong Prev Outpt Svc,Ea Addl 30 min
 ;;^UTILITY(U,$J,358.3,25151,1,4,0)
 ;;=4^G0514
 ;;^UTILITY(U,$J,358.3,25152,0)
 ;;=G2086^^88^1130^51^^^^1
 ;;^UTILITY(U,$J,358.3,25152,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,25152,1,2,0)
 ;;=2^Outpt Based Opioid Tx,70 min
 ;;^UTILITY(U,$J,358.3,25152,1,4,0)
 ;;=4^G2086
 ;;^UTILITY(U,$J,358.3,25153,0)
 ;;=G2087^^88^1130^50^^^^1
 ;;^UTILITY(U,$J,358.3,25153,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,25153,1,2,0)
 ;;=2^Outpt Based Opioid Tx,60 min
 ;;^UTILITY(U,$J,358.3,25153,1,4,0)
 ;;=4^G2087
 ;;^UTILITY(U,$J,358.3,25154,0)
 ;;=G2088^^88^1130^52^^^^1
 ;;^UTILITY(U,$J,358.3,25154,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,25154,1,2,0)
 ;;=2^Outpt Based Opioid Tx,Ea Addl 30 min 
 ;;^UTILITY(U,$J,358.3,25154,1,4,0)
 ;;=4^G2088
 ;;^UTILITY(U,$J,358.3,25155,0)
 ;;=U07.1^^89^1131^1
 ;;^UTILITY(U,$J,358.3,25155,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,25155,1,3,0)
 ;;=3^Confirmed COVID-19
 ;;^UTILITY(U,$J,358.3,25155,1,4,0)
 ;;=4^U07.1
 ;;^UTILITY(U,$J,358.3,25155,2)
 ;;=^5159070
 ;;^UTILITY(U,$J,358.3,25156,0)
 ;;=U09.9^^89^1131^2
 ;;^UTILITY(U,$J,358.3,25156,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,25156,1,3,0)
 ;;=3^Post COVID-19 Condition,Unspec
 ;;^UTILITY(U,$J,358.3,25156,1,4,0)
 ;;=4^U09.9
 ;;^UTILITY(U,$J,358.3,25156,2)
 ;;=^5161298
 ;;^UTILITY(U,$J,358.3,25157,0)
 ;;=Z20.822^^89^1132^1
 ;;^UTILITY(U,$J,358.3,25157,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,25157,1,3,0)
 ;;=3^Contact w/ & Exposure to COVID-19
 ;;^UTILITY(U,$J,358.3,25157,1,4,0)
 ;;=4^Z20.822
 ;;^UTILITY(U,$J,358.3,25157,2)
 ;;=^5160187
 ;;^UTILITY(U,$J,358.3,25158,0)
 ;;=J20.8^^89^1133^1
 ;;^UTILITY(U,$J,358.3,25158,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,25158,1,3,0)
 ;;=3^Bronchitis,Acute d/t Other Spec Organisms
 ;;^UTILITY(U,$J,358.3,25158,1,4,0)
 ;;=4^J20.8
 ;;^UTILITY(U,$J,358.3,25158,2)
 ;;=^5008194
